Randomized phase II trial of parsatuzumab (Anti-EGFL7) or placebo in combination with FOLFOX and bevacizumab for first-line metastatic colorectal cancer

  1. García-Carbonero, R.
  2. Van Cutsem, E.
  3. Rivera, F.
  4. Jassem, J.
  5. Gore, I.
  6. Tebbutt, N.
  7. Braiteh, F.
  8. Argiles, G.
  9. Wainberg, Z.A.
  10. Funke, R.
  11. Anderson, M.
  12. McCall, B.
  13. Stroh, M.
  14. Wakshull, E.
  15. Hegde, P.
  16. Ye, W.
  17. Chen, D.
  18. Chang, I.
  19. Rhee, I.
  20. Hurwitz, H.
Revue:
Oncologist

ISSN: 1549-490X,  1083-7159

Année de publication: 2017

Volumen: 22

Número: 4

Type: Article

DOI: 10.1634/THEONCOLOGIST.2016-0133 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus